Alendronate Sodium Tablet
Product Images NDC 50090-3126

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 50090-3126). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Alendronate Fig1)

A line graph titled 'Cumulative Incidence of Hip Fractures in the Three-Year Study of FIT' showing cumulative incidence (%) on the y-axis and time in months on the x-axis. Two lines represent placebo and Alendronate Sodium groups, with Alendronate Sodium showing a lower cumulative incidence of hip fractures over 36 months in patients with radiographic vertebral fracture at baseline.*

FDA Label Image

Figure 2 (Alendronate Fig2)

Bar chart illustrating bone mineral density (BMD) mean percentage increase relative to placebo after three years of Alendronate 10 mg/day treatment in postmenopausal women from U.S. and multinational osteoporosis studies. BMD increases are shown for lumbar spine, femoral neck, and trochanter with error bars indicating standard error.*

FDA Label Image

Figure 3 (Alendronate Fig3)

Two line graphs comparing the effect of Alendronate 10 mg/day versus placebo on lumbar spine bone mineral density (BMD) percent change from baseline in postmenopausal women over 36 months. The U.S. study graph shows a steady increase in BMD for Alendronate and no change for placebo. The multinational study graph shows a similar trend with BMD increase for Alendronate and stable or slight decrease for placebo.*

FDA Label Image

Figure 4 (Alendronate Fig4)

Two bar charts showing osteoporosis prevention studies in postmenopausal women, illustrating the mean percent change in bone mineral density (BMD) from baseline over 2-year and 3-year periods. The charts compare BMD changes with Alendronate 5 mg/day versus placebo at lumbar spine, femoral neck, trochanter, and total body sites.*

FDA Label Image

Studies In Glucocorticoid (Treated Patients Increase in BMD Alendronate 5 mg/day at One Year)

A bar graph showing the mean percentage increase in bone mineral density (BMD) at the lumbar spine, femoral neck, and trochanter sites relative to placebo, with standard error bars, for glucocorticoid-treated patients taking Alendronate 5 mg/day for one year. Two groups are compared: U.S. patients and multinational patients.*

FDA Label Image

Studies In Paget's Disease Of Bone Effect On Serum Alkaline Phosphatase Of Alendronate 40 mg/day Versus Placebo Or Etidronate 400 mg/day (Alendronate Fig6)

A line graph showing the effect on serum alkaline phosphatase in Paget's Disease of Bone for Alendronate 40 mg/day compared to placebo and Etidronate 400 mg/day over 6 months. The y-axis represents mean percent change from baseline ± SE, and the x-axis shows time in months. Data include results from multinational and U.S. studies, with sample sizes noted for each group.*

FDA Label Image

Chemical Structure (Alendronate Str)

FDA Label Image

Label Image (Lbl500903126)

Alendronate Sodium 70 mg oral tablets label from A-S Medication Solutions. Label indicates the product name, strength (70 mg), dosage form (tablets), storage instructions (store at 68 to 77 degrees Fahrenheit), quantity (4 tablets), and provides a lot number and product number. The label also notes that each tablet contains 91.36 mg of Alendronate Sodium USP equivalent to 70 mg of Alendronic Acid.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.